Bcell Design develops and manufactures chimeric monoclonal antibodies with human-like characteristics for in vitro diagnostics. We provide a secure and reliable source of raw material as a best alternative to disease state plasma and human serum, currently used as calibrators, positive controls or quality controls. Through its technological platform, built upon 15 years’ expertise in mAb and early-stage immunotherapy development, IVD developers and manufacturers gain access to a wide range of antibodies that are immediately ready for testing in human models. Founded in 2007 and from one of the few laboratories of excellence internationally recognized for their expertise in the control of the expression of immunoglobulin genes, and located in Limoges, France. Bcell Design recently reinforced its industrial capabilities alongside Inoviem Scientific, its major shareholder since the end of 2021, to enlarge the offer of disruptive antibodies development and manufacturing for IVD field. Bcell Design is a member of the biotech division of the DMS Group through Hybrigenics Pharma and Inoviem Scientific, and currently employs 11 staff.